Scientific article
Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
Contributors
Pritchard-Jones, Kathy; Bergeron, Christophe; de Camargo, Beatriz; van den Heuvel-Eibrink, Marry M; Acha, Tomas; Godzinski, Jan; Oldenburger, Foppe; Boccon-Gibod, Liliane; Leuschner, Ivo; Vujanic, Gordan; Sandstedt, Bengt; de Kraker, Jan; van Tinteren, Harm; Graf, Norbert; SIOP Renal Tumours Study GroupCollaborators
Ansari Djaberi, Marc Georges
Published in
The Lancet, vol. 386, no. 9999, p. 1156-1164Publication date
2015Abstract
Keywords
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
- Chemotherapy, Adjuvant/adverse effects/methods
- Child
- Child, Preschool
- Dactinomycin/administration & dosage/adverse effects
- Doxorubicin/administration & dosage/adverse effects
- Female
- Humans
- Infant
- Kaplan-Meier Estimate
- Kidney Neoplasms/drug therapy/pathology/surgery
- Male
- Neoadjuvant Therapy/adverse effects/methods
- Neoplasm Staging
- Nephrectomy
- Treatment Outcome
- Vincristine/administration & dosage/adverse effects
- Wilms Tumor/drug therapy/pathology/surgery
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
PRITCHARD-JONES, Kathy et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms” tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. In: The Lancet, 2015, vol. 386, n° 9999, p. 1156–1164. doi: 10.1016/S0140-6736(14)62395-3
Main files (1)
Article (Published version)
Secondary files (1)
Appendix
Identifiers
- PID : unige:97169
- DOI : 10.1016/S0140-6736(14)62395-3
- PMID : 26164096
